Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.（NTLA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · NTLA · 截至 2026年6月8日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
20
近12个月
买卖比
0.10
Buy/Sell (by trades)
整体情绪
Intellia Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
NTLA 季度内部人买卖趋势
NTLA 内幕交易卖出 · NTLA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · NTLA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
NTLA 高管卖出股份 · NTLA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Mar 1, 2026 | LEONARD JOHN M President and CEO · Director | Award | 156,400 | — | Form 4 |
| Mar 1, 2026 | BASTA JAMES EVP, General Counsel | Award | 46,080 | — | Form 4 |
| Mar 2, 2026 | BASTA JAMES EVP, General Counsel | Sale | 1,211 | $17K | Form 4 |
| Mar 1, 2026 | Lebwohl David EVP, Chief Medical Officer | Award | 9,943 | — | Form 4 |
| Mar 1, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Award | 61,280 | — | Form 4 |
| Mar 1, 2026 | Schultes Birgit C EVP, Chief Scientific Officer | Award | 39,200 | — | Form 4 |
| Mar 1, 2026 | Clark Eliana EVP, Chief Technical Officer | Award | 7,353 | — | Form 4 |
| Mar 2, 2026 | Clark Eliana EVP, Chief Technical Officer | Sale | 607 | $8K | Form 4 |
| Mar 1, 2026 | Dube Michael P VP, Chief Accounting Officer | Award | 17,250 | — | Form 4 |
| Jan 5, 2026 | LEONARD JOHN M President and CEO · Director | Sale | 34,146 | $314K | Form 4 |
| Jan 5, 2026 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | 8,508 | $78K | Form 4 |
| Jan 5, 2026 | BASTA JAMES EVP, General Counsel | Sale | 10,397 | $96K | Form 4 |
| Jan 5, 2026 | Cohen Fred E Director | Purchase | 150,000 | $1.40M⚡ | Form 4 |
| Jan 5, 2026 | Lebwohl David EVP, Chief Medical Officer | Sale | 11,903 | $110K | Form 4 |
| Jan 5, 2026 | Clark Eliana EVP, Chief Technical Officer | Sale | 9,515 | $88K | Form 4 |
| Jan 5, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sale | 6,379 | $59K | Form 4 |
| Jan 5, 2026 | Dube Michael P VP, Chief Accounting Officer | Sale | 2,989 | $28K | Form 4 |
| Dec 11, 2025 | LEONARD JOHN M President and CEO · Director | Option | 49,959 | $341K | Form 4 |
| Dec 11, 2025 | LEONARD JOHN M President and CEO · Director | Sale | 49,959 | $474K | Form 4 |
| Dec 12, 2025 | LEONARD JOHN M President and CEO · Director | Option | 8,557 | $58K | Form 4 |
| Dec 11, 2025 | LEONARD JOHN M President and CEO · Director | Sale | 32,832 | $311K | Form 4 |
| Dec 11, 2025 | LEONARD JOHN M President and CEO · Director | Sale | 5,355 | $51K | Form 4 |
| Oct 1, 2025 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | 31 | $539 | Form 4 |
| Oct 1, 2025 | Dube Michael P VP, Chief Accounting Officer | Sale | 1,871 | $33K | Form 4 |
| Aug 20, 2025 | CHASE WILLIAM J Director | Purchase | 100,000 | $1.00M⚡ | Form 4 |
Schultes Birgit C
EVP, Chief Scientific Officer
日期
Jan 5
股数
8,508
均价
$9.21
总金额
$78K
Dulac Edward J III
EVP, Chief Financial Officer
日期
Jan 5
股数
6,379
均价
$9.21
总金额
$59K
LEONARD JOHN M
President and CEO · Director
日期
Dec 11
股数
49,959
均价
$6.83
总金额
$341K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 NTLA 内幕交易
NTLA 内幕交易
Intellia Therapeutics, Inc.（NTLA）内幕交易数据来源于公司内部人（包括LEONARD JOHN M (President and CEO · Director), Clark Eliana (EVP, Chief Technical Officer), Dube Michael P (VP, Chief Accounting Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。NTLA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Intellia Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
NTLA 内幕交易 · 5个问题Intellia Therapeutics, Inc.（NTLA）的内部人包括高管和董事，如LEONARD JOHN M (President and CEO · Director), Clark Eliana (EVP, Chief Technical Officer), Dube Michael P (VP, Chief Accounting Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026